Background 30 Metabolic reprograming, non-mutational epigenetic changes, increased cell plasticity and 31 multidrug tolerance are early hallmarks of therapy resistance in cancer. In this temporary, 32 therapy-tolerant state, cancer cells are highly sensitive to ferroptosis, a form of regulated cell 33 death that is caused by oxidative stress through excess levels of iron-dependent peroxidation 34 of polyunsaturated fatty acids (PUFA). However, mechanisms underpinning therapy-induced 35 ferroptosis hypersensitivity remain to be elucidated.
ATT pre-treated cells were seeded as described above. For quantifying C16:0 fatty acid uptake, 250 growth media was exchanged with 65 µl/well of serum-free RPMI media (Thermo Fisher) 251 supplemented with 0.2% BSA (lipid-free, Sigma) and C16:0-Bodipy (5 µM, Thermo Fisher) 252 and Mitotracker Orange CMTMRos (0.4 µM, Thermo Fisher) and incubated at 37°C for one 253 hour. For quantifying cholesterol uptake, media was exchanged with 65 µl/well of serum-free 254 RPMI media (0.2% lipid-free BSA) supplemented with 15 µM NBD Oxa-1,3-Diazol-4-yl) Amino-23,24-Bisnor-5-Cholen-3β-Ol, Thermo Fisher) and incubated at 256 37°C for 2 hours. For quantifying lipoprotein complex uptake, media was exchanged with 65 257 µl/well of serum-free RPMI media (0.2% lipid-free BSA) supplemented with 1,1'-Dioctadecyl-258 3,3,3',3'-Tetramethylindocarbocyanine (DiI)-labelled acetylated-LDL (15µg/ml, Thermo 259 Fischer) or DiI-labelled LDL (15 µg/ml, Thermo Fisher) and incubated at 37°C for 2 hours. 260 Phosphatidylethanolamine uptake was measured as described above in serum-free RPMI media 261 (0.2% lipid-free BSA) or, where noted, in conditioned media by incubation of cells at 37°C for 262 1 hour with NBD-PE (5 µM, 22-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)-1, 2-263 Dihexadecanoyl-sn-Glycero-3-Phosphatidylethanolamine) triethylammonium salt, Thermo 264 Fisher). After incubation, cells were fixed with 4% PFA. Cellular DNA and F-actin was then 265 counterstained with DAPI and Alexa Fluor 647 Phalloidin (Thermo Fisher). Image acquisition 266 and quantitative analysis were performed as described above. 267 For measuring cellular uptake of lyso-PC-A2, cells were seeded and processed as described pentanoic acid (Thermo Fisher) suggested a passive and slow route of cellular uptake when 280 compared to longer chain FAs (C12:0 and C16:0, data not shown). Following the incubation, 281 cells were fixed with 4% PFA, and cellular DNA and F-actin was then counterstained with 282 DAPI and Alexa Fluor 647 Phalloidin (Thermo Fisher). Image acquisition and quantitative 283 analysis were performed as described above. Lyso-PC-A2 uptake was calculated as ratio of 284 green (cleaved lyso-PC-A2) vs red (uncleaved PC-A2) signal. 285 Membrane fluidity (differences in membrane lipid packaging) was measured by live ratio-286 fluoresce microscopy of ATT pre-treated cells after incubation in 80 µl/well of DPBS 287 supplemented with 1 µM di-4-ANEPPDHQ (D36802, Thermo Fisher) for 30 min at 37°C. 288 DNA was counterstained with Hoechst 33342 (1 µg/ml, Sigma-Aldrich) and cells were washed 289 once with DPBS. di-4-ANEPPDHQ labeled cells (n>750 cells, 8 wells/sample, 2 biological 290 replicates) were imaged at 560 nm and 650 nm using the InCell 2200 System, where a spectral 291 red shift is indicative of an increase in the disordered/liquid phase of the plasma membrane. 292 Quantitative image analysis and calculation of the 560nm/650nm ratio was carried out with 293 CellProfiler software. 294 Lipid peroxidation was measured by live ratiometric fluorescence microscopy of ATT pre-295 treated cells after incubation in 65 µl/well of serum-free RPMI media (0.2% lipid-free BSA) 296 supplemented with 5 µM with BODIPY 581/591 C11 (Thermo Fisher) for 60 min at 37°C.
297
Peroxidation of the polyunsaturated butadienyl portion of the fluorescent dye results in a 298 spectral fluorescence emission shift from orange (~590 nm) to green (~510 nm).
Measurement of cell confluence and qSCI of cell death 300
Cell proliferation as a function of increasing cell confluence was measured by live imaging 301 microscopy with the IncuCyte FLR and Zoom system (Essen BioScience, Ann Arbor, 302 Michigan, USA). Parental or ATT pre-treated PCa cells were seeded as described above in 96-303 well Essen ImageLockTM plates (Essen BioScience, Ann Arbor, Michigan, USA). Images 304 were acquired at 2 hour intervals with a 10x objective for up to 7 days.
305
For assessment of cell death, cells were seeded in 96 well plates (n=3 wells/treatment with 306 >4000 cells/wells) as described above and treated with indicated compounds. At the end of the 307 treatment period, cells were co-stained with Hoechst 3342 (1 µg/ml, total cell count) and 308 propidium iodide (5 µg/ml, Sigma-Aldrich, dead cells). Cells were imaged using the InCell 309 2200 System, the images were analyzed with Cell Profiler software (Broad Institute) for total 310 and dead cell count, and the percentage of dead cells was calculated based on the ratio of dead 311 and total cells. Nonadecanoic acid (C19:0)) was added and briefly vortexed. 770 µL MTBE was added and 318 mixture was incubated for 1 h at room temperature in a shaker. Phase separation was induced 319 by adding 200 µL NH4CH3CO2 (150 mM). After vortexing for 20 s, the sample was 320 centrifuged at 2,000 g for 5 min. The upper (organic) phase was collected and stored at -80°C, 321 then diluted into 2:1 MeOH:CHCl3 with 7.5 mM NH4CH3CO2 for mass spectrometry analysis.
322
Tandem mass spectrometry (MS) of the intact lipids was performed using a triple quadrupole 323 mass spectrometer (6500 QTRAP, SCIEX, ON, Canada). The lipid extracts (as described 324 above) were diluted 40-fold prior to analysis. Samples were directly infused into the 325 electrospray ionization source of the mass spectrometer using a loop injection method, where 326 100 µL of sample was loaded into a sample loop using an autosampler and subsequently infused 327 into the mass spectrometer by electrospray ionization at a flow rate of 20 µL/min. Lipid classes 328 were targeted using either precursor ion or neutral loss scans. For quantification, SPLASH was 329 added to cells prior to lipid extraction. Tandem MS data was processed using LipidView 330 (version 1.3beta; SCIEX) using predefined target lists.
331
Hydrolysis and derivatization of lipids extracts to fatty acid methyl esters (FAME) was 332 performed on-line using trimethylsulfonium hydroxide [32] . FAMEs were analyzed with a gas 333 chromatograph coupled to a mass spectrometer (GC/MS -TQ8040; Shimadzu, Kyoto, Japan).
334
The separation was carried out on a RTX-2330 capillary column (cyanopropyl stationary phase, 335 60 m x 0.25 mm, film thickness 0.20 μM; Restek, Bellefonte, PA, USA) and the electron 336 ionization energy was set at 70 eV. Conditions for the analysis of FAMEs were as follows: 337 carrier gas, He: column flow at 1 mL/min; 22:1 split ratio, injection volume 1 μL; injector 338 temperature 240 o C; interface and ion source temperature 260 o C. GC oven temperature was 339 maintained at 100 o C for 1 min, thermal gradient 100 °C to 140 o C at 10 o C / min, 140 °C to 340 175 o C at 6 o C / min, 175 °C to 200 o C at 10 o C / min and hold for 1 min, followed by 200 °C 341 to 250 o C at 5 o C / min and hold for 4 mins. The data were acquired with Q3 scan mode from 342 m/z 50 -650. For data collection the MS spectra were recorded from 4.6 min to 28.33 mins.
343
The data was processed in GC/MS solution software (Shimadzy, Kyoto, Japan). Fatty acids 344 were identified based on retention time alignment with reference FAMEs from a mixture of 345 standards (Food Industry FAME mix (Table S6) , Restek, Bellefonte, PA USA). All samples 346 were normalized to internal standard C19:0 and peak areas of relevant FAMEs was subtracted 347 from negative control samples.
348 349 13 C carbon tracing of metabolites by mass spectrometry 350 LNCaP cells were treated with DMSO or Enzalutamide (10 µM) for up to 21 days as 351 described above. 72 hours prior to harvesting, media was replaced with complete growth 352 media supplemented with uniformly labelled 13 C-acetate (500 µM, Sigma-Aldrich).
353
Metabolites were extracted using 80% methanol in water extraction buffer (Sigma) that was 354 supplemented with uniformly deuterated myristic acid (2 µM, Sigma) as an internal control.
355
Samples were normalized based on total protein measurements in precipitates by Table S2 ). suppressed genes ( Fig. S2B ) did not change, suggesting that AR activity remained suppressed.
436
Consistent with the de-differentiation effect of AR-antagonism, transcriptional levels of several 437 stemness markers were significantly increased (Table S1 ) [36] . Furthermore, Enz-treated 438 LNCaP cells showed a time-dependent strong reduction in cellular reducing power (-70%),
439
ATP levels (-60%) and mitochondrial membrane potential (-30%), which stabilized after 14 440 days ( Fig. 2C, Fig. S2C ). Proliferation almost completely ceased after 14 days of Enz treatment, 
486
Of the top 50 deregulated lipid species measured, 86% of these were found to have increased 487 abundance with increasing time of Enz treatment (Fig. S3I) . Notably, the majority of these 488 were PC and PE phospholipids that make up ~70% of the lipid content of mammalian cells 489 [41], providing further evidence that Enz increased cellular lipid content. Together, qSCI and 490 lipidomics analyses demonstrated that Enz induced substantial remodeling of all major lipid 491 classes, leading to a net increase in cellular lipid content.
493
Enhanced lipid uptake fuels cellular lipid accumulation 494 As shown above, therapy-induced persister cells displayed multidrug tolerance to lipogenesis 495 inhibitors ( Fig. 2D ), suggesting that de novo synthesis played a limited role in cellular lipid 496 accumulation. Indeed, metabolic tracing of 13 C-acetate by mass spectrometry revealed that de 497 novo cholesterol synthesis decreased by 71% (p>0.0001) after Enz treatment of LNCaP cells 498 for 21 days when compared to control (Fig. 4A) . No significant incorporation of 13 C-glucose, another key carbon source for lipogenesis, into lipids was measured (data not shown), and 500 already low basal glucose uptake was significantly reduced by Enz (Fig. S4A ). Consistent with 501 this, transcriptomics and proteomics analysis showed that key enzymes of de novo cholesterol 502 and FA synthesis pathways were significantly downregulated by Enz treatment (Fig. 4B , Table   503 S1), suggesting that alternative lipid supply pathways were responsible for therapy-induced 504 lipid accumulation.
505
To measure cellular lipid uptake, qSCI with various fluorophore labeled lipid probes (NBD- Enz. (Fig. 4F) . Surprisingly, uptake of saturated free FA (Bodipy-C16:0) was drastically 524 decreased by both androgen-depleted serum (CSS) and Enz treatment over time (Fig. 4G) , 525 suggesting that ATT-induced changes to transporter-mediated lipid uptake are specific. Gas Above results showed that Enz affected all major lipid classes and strongly increased cellular 541 content of phospholipids, suggesting changes to membrane composition and function. Enz treatment compared to control (Fig. 5A) . Similar trends were seen in SM, PC, PE, PS, and 546 PG lipid classes ( Fig. S3B-F) , where an enrichment of phospholipids with long-chain PUFAs 547 was observed. Integrated analyses of all dysregulated fatty acid species detected by GC/MS 548 FAME analysis (Fig. S4C) or proteins detected by proteomics ( Fig. S1B) with the mRNA 549 expression changes by microarray (Fig. 2) of LNCaP cell treated with vehicle control or Enz 550 for 21 days demonstrated significant enrichment of multiple pathways involved in PUFA 551 metabolism ( Fig. S5A ), including those of essential PUFAs (e.g. linoleic acid and arachidonic 552 acid).
553
Consistent with increased PUFA content, Enz-treated LNCaP cells displayed increased 554 membrane fluidity (Fig. 5B ). Regarding the mechanisms underlying the increase in 555 desaturation and elongation of PUFAs, we noted a significant reduction of PUFA containing Table S1 ). In support of this, a review of microarray data from our LNCaP tumor xenograft 561 model of CRPC progression [33] revealed that the expression of elongases and desaturases was 562 overall reduced in regressing tumors and tumors at PSA nadir when compared to tumors from 563 sham-castrated mice ( Fig. S5B and S5C) . Notably, this expression pattern reversed and 564 increased in recurring tumors and CRPC when compared to tumors from sham-castrated mice.
565
Furthermore, FA elongation and de novo FA synthesis share the requirement of malonyl-CoA 566 as a C2 carbon donor, which is produced by acetyl-CoA carboxylase (ACACA). As shown in 567 ( Fig. 4B ), ACACA mRNA expression was reduced, providing further support that Enz-treated 568 cells were increasingly acquiring PUFAs from uptake of serum-derived lipids (Fig. S4D ) and 
656
Previous studies of resistance to androgen receptor-targeted therapies (ATTs) in PCa analyzed 657 models after extensive treatment periods (months to years) with fully developed resistance as 658 indicated by reactivated cell proliferation [6, 8, 34, 35] . Different to these studies, we 659 hypothesized that delineating early events of ATT-induced metabolic reprogramming might 660 provide novel co-targets that could extend the efficacy of ATTs, thereby delaying therapy 661 failure and disease progression to currently incurable CRPC and Enz-resistant CRPC.
662
Our longitudinal study of the early adaptive response to androgen deprivation therapy (ADT) 663 and Enz (0-21 days) in PCa cells made several key discoveries related to reprogrammed lipid 664 metabolism (summarized in Fig. 6 ). Moreover, our work provided several novel potential 665 targets for intervention strategies to combat ATT resistance that need pre-clinical evaluation.
666
Importantly, our study is first in class to demonstrate that therapy-induced lipid remodeling 667 and lipid supply plasticity are critical mechanisms that underpin GPX4 dependence and 668 ferroptosis hypersensitivity in persister cells. Thus, our findings might have wider implications 669 for our understanding of early events of therapy resistance since GPX4 dependence has been 670 reported in several types of cancer in response to different targeted therapies [9, 49] .
671
Consistent with previous studies that showed that subpopulations of breast and lung cancer (Table S1 ), suggesting that increased acylceramide 689 synthesis and lipid droplet storage caused the measured changes to lipid droplet morphometry.
690
Ceramide metabolism was also highlighted by our comparative gene signature analysis (Fig.   691 S1C). Given the heterogeneous nature of lipid droplets within cell populations [60] and that 692 their accumulation has recently been described as a mechanism of drug resistance in colorectal 
695
Aimed to identify the source of increased lipid content, stable isotope carbon tracing revealed 696 little glycolytic contribution to FA and cholesterol synthesis (data not shown) and a 70% 697 reduction of cholesterol synthesis from acetate-derived carbon (Fig. 4A) . While lipogenesis can be fueled by other carbon sources (glutamine and FAs), enhanced lipid synthesis from 699 alternative fuels was not supported by the measured bioenergetic, redox and mitochondrial 700 activity statuses (Fig. 2C) . Moreover, the transcriptome and proteome changes of Enz-treated 701 LNCaP cells collectively indicated a reduction in oxidative phosphorylation (Fig. 2B ) and, 702 more importantly, a decrease of multiple key enzymes of de novo FA and cholesterol 703 biosynthesis (Fig. 4B) . These results were consistent with reduced toxicity of several 704 lipogenesis inhibitors (Figs. 2D and S2G) . Instead, therapy-induced lipid remodeling and 705 increased lipid content was fueled by enhanced lipid uptake via cargo-selective (transporters, 706 Fig. 4C-F) and non-selective uptake mechanisms (macropinocytosis and TNTs, Figs. S4E and 707 S4F). We frequently observed mitochondria and lipid droplets within Enz-induced TNTs (Fig.   708 S4F), suggesting that these conduits of intercellular transport might contribute considerable 709 amounts of lipid biomass. Similarly, macropinocytosis of cell debris including membrane 710 components have been previously shown to significantly contribute to the cellular lipid pool 711 [45] . Notably, the lipid supply switch to uptake excluded uptake of saturated FAs as indicated 712 by reduced uptake of C16:0-Bodipy after extended ATT treatments (Enz and ADT, Fig. 4G ),
713
indicating that other uptake mechanisms or transporters were responsible for the increased 714 cellular levels of saturated FAs and PUFAs. Together, these results demonstrate that ATTs 715 induced a switch of lipid supply from a mix of de novo synthesis and exogenous sources to 716 predominantly uptake of exogenous lipids via multiple mechanisms. Thus, lipid supply 717 plasticity is a novel metabolic mechanism associated with ATT resistance development in PCa, 718 and enhanced lipid scavenging can serve purposes other than biomass and energy production 719 to support malignant cell proliferation. It is therefore critical to acknowledge that lipid supply 720 plasticity during the development of ATT resistance limits the therapeutic window of 721 individual treatments directed against either uptake or synthesis.
722
Only recently has attention been given to lipid uptake and to map the lipid transporter landscape including PCa, estimated that >70% of the lipid-derived carbon biomass is derived from uptake 745 and only 30% from synthesis based on carbon tracing of serum-derived free FAs [65, 66] . 746 However, these estimates are limited by the fact that the serum lipidome is highly complex and 747 that >95% of serum FAs are acyl conjugates across all lipid classes, including TAGs, CEs and 748 phospholipids. Thus, the carbon contribution from the collective uptake of all lipid classes to 749 lipid biomass in proliferating cancer cells is likely to be even higher than the above estimates.
750
Despite this knowledge gap, we showed that blocking cholesterol uptake via NPC1 inhibition 751 with U18666A (Fig. 5H) is a promising strategy to exploit the increased demand of ATT-752 treated PCa cells for exogenous cholesterol (Fig. 4C ). Cholesterol is a critical storage lipid (as 753 acyl-ester in lipid droplets) and serves as a precursor for the steroidogenic pathway in which 754 testosterone can be endogenously synthesized in PCa tumors [67] , and that activation of the farnesyl diphosphate) that are critical for GPX4 [11] and FSP1 activities [13, 14] .
767
In addition to Enz-enhanced lipid uptake and content, our work described extensive lipid 768 remodeling that was characterized by increased FA elongation and desaturation (Fig. 5A) where oncogenic growth signaling occurs [71, 74] . Enz-induced high PUFA levels in 773 phospholipids were associated with increased membrane fluidity ( Fig 5B) which is thought to 774 play a role in reduced sensitivity to chemotherapy reagents (i.e. multidrug tolerance, Fig. 2D ) 775 [75] and increases permeability and cell mobility and facilitates membrane-centered biological (Fig. 5D ). If not enzymatically repaired by 780 GPX4 at the expense of reduced glutathione, accumulation of lipid hydroperoxides can lead to 781 cell death via ferroptosis. Consistent with this, Enz-treated PCa cells showed reduced reductive 782 power and hypersensitivity to selective GPX4 inhibitor, RSL3 (Fig. 5E ). ADT and Enz-induced 783 sensitivity to GPX4 inhibition of PCa cells was reminiscent of lapatinib-and vemurafenib-784 induced drug tolerance and emergence of "persister cells" in melanoma, breast, lung and 785 ovarian cancer [9] and therapy-resistance-associated high-mesenchymal state cancer cells [78] . 786 It was speculated that GPX4 dependence in these therapy-induced states relied on the FA 787 composition of the lipid bilayers. Our results of therapy-induced lipid remodeling causing 788 PUFA enrichment provides first-in-class evidence to support this hypothesis. More 789 importantly, the diversity of targeted therapies causing this shared GPX4 dependence suggests 790 that lipid remodeling leading to PUFA enrichment of phospholipids might be a common 791 mechanism associated with therapy resistance that could be pursued as therapeutic target in 792 multiple types of cancer. However, the therapeutic window is likely to be small and restricted 
Figure Legends

